Adaptimmune Therapeutics (ADAP) Tops Q1 EPS by 9c
Tweet
Share
E-mailGet Alerts ADAP Hot Sheet
Join SI Premium – FREE
Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 EPS of ($0.03), $0.09 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $7.29 million versus the consensus estimate of $7.55 million.
For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Starts Holley (HLLY) at Buy
- Lockheed Martin wins $607M in defense contracts
- U.S. military says it is striking Iran over Strait of Hormuz attacks
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
